RxDoctor Payments Data

Daniel Witheiler, MD

MOHS-Micrographic Surgery · Dallas, TXNPI 1023083482

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 24.6% of the total.

$5,643in general payments, 2019–2025

Across 249 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$623
  • Sanofi$562
  • Arcutis Biotherapeutics, Inc.$492
  • Johnson & Johnson$317
  • Sun Pharmaceutical Industries Inc.$270
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,54498%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,643 in reported general payments places this provider in the 75th percentile of 109 mohs-micrographic surgery providers in Texas.

See all mohs-micrographic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$437,556
Medicare patients
331
Services billed
1,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab24$96,244
Doxycycline Hyclate118$1,075
Ketoconazole43$721
Betamethasone Dipropionate16$720
Triamcinolone Acetonide50$460
Cephalexin88$359
Mupirocin21$123
Finasteride15$105

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →